Core Viewpoint - Watson Bio (300142) is focusing on mRNA technology platform, synthetic biology manufacturing, microecological health, and functional nutrition intervention as key areas for development [1] Group 1: Business Developments - The company has submitted clinical trial applications for respiratory syncytial virus mRNA vaccine and lyophilized varicella-zoster virus mRNA vaccine to the National Medical Products Administration, which have been accepted [1] - Ongoing developments in synthetic biology manufacturing, microecological health, and functional nutrition intervention are being actively pursued [1] Group 2: Future Outlook - Investors are encouraged to keep an eye on the company's information disclosures for updates on the progress of various business initiatives [1]

Core Viewpoint - Yunnan Watson Bio (300142) has announced the signing of a revised exclusive sublicensing agreement with Notitia Biotechnologies Company, expanding their collaboration into the "non-patient" field, which aims to enhance the development and commercialization of core microbiome therapies in precision microbiome health and functional nutrition interventions [1] Group 1 - The board of directors of Watson Bio approved the amendment to the exclusive sublicensing agreement with Notitia [1] - The original exclusive sublicensing agreement was signed on May 23, 2025, focusing on the "patient field" [1] - The revised agreement will cover relevant intellectual property and proprietary technology in the non-patient field, indicating a strategic expansion of their partnership [1] Group 2 - The signing of this amendment signifies Watson Bio's dual strategy of "disease treatment intervention" and "chronic disease prevention + health nutrition" [1] - The company aims to establish a comprehensive health solution that encompasses in-hospital treatment, out-of-hospital management, and multi-scenario interventions [1]

Core Points - Watson Bio announced a board meeting on July 30, 2025, to approve a revised agreement that expands the scope of "core microbiome therapy" into precision microbiome health and functional nutrition intervention [1] - The revision includes granting exclusive rights for development, manufacturing, and commercialization in mainland China, Hong Kong, and Macau for non-patient populations [1] - The financial terms, duration, and due diligence clauses of the agreement have been amended, but the signing will not significantly impact the company's operating performance for the current year [1]